Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
LifeStance Health Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was -103.85%.
The industry rank for LifeStance Health Group's 3-Year RORE % or its related term are showing as below:
LFST's 3-Year RORE % is ranked worse than 92.75% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 0.74
vs LFST: -103.85
LifeStance Health Group (NAS:LFST) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
LifeStance Health Group 3-Year RORE % Related Terms
LifeStance Health Group 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, LifeStance Health Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeStance Health Group 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LifeStance Health Group's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where LifeStance Health Group's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
LifeStance Health Group (LFST) has a 3-Year RORE % of -103.85 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LifeStance Health Group and its competitors. According to the industry distribution chart, LifeStance Health Group ranks #563 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 92.8%.
Is LifeStance Health Group's 3-Year RORE % too high?
LifeStance Health Group's current 3-Year RORE % is -103.85. Based on the distribution chart, LifeStance Health Group ranks #563 out of 607 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, LifeStance Health Group has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's 3-Year RORE % compare to NHC and BKD?
According to the Healthcare Providers & Services industry distribution chart, LifeStance Health Group ranks #563 out of 607 companies for 3-Year RORE %. This places LifeStance Health Group in the lower half of its industry. The industry median 3-Year RORE % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LifeStance Health Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeStance Health Group's current 3-Year RORE % is -103.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.22, compared to a current price of $9.65 — trading 17.4% above its estimated fair value. The current 3-Year RORE % is -103.85. LifeStance Health Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current 3-Year RORE % is -103.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeStance Health Group (LFST) Overvalued in 2026?
Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued.
The current stock price of $9.65 is trading 17.4% above its estimated GF Value™ of $8.22.
GuruFocus considers LifeStance Health Group to be Modestly Overvalued.
Key valuation signals for LFST:
3-Year RORE %: -103.85
GF Value™: $8.22 vs. price of $9.65 (17.4% above fair value)
No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
57GF Score
Get the complete analysis for LFST
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFST has been successfully added to your 
